Federated Hermes’s Structure Therapeutics GPCR Stock Holding History

Federated Hermes’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,500	Closed	-$126K	–	2123
2025 Q3	$126K	Sell	4,500 -463,800	-99%	-$9.24M	﹤0.01%	1551
2025 Q2	$9.71M	Sell	468,300 -702,648	-60%	-$15.4M	0.02%	584
2025 Q1	$20.3M	Sell	1,170,948 -875,010	-43%	-$21.4M	0.04%	398
2024 Q4	$55.5M	Sell	2,045,958 -365,642	-15%	-$13M	0.12%	220
2024 Q3	$106M	Buy	2,411,600 +4,394	+0.2%	+$170K	0.23%	108
2024 Q2	$94.5M	Buy	2,407,206 +150,000	+7%	+$6.16M	0.22%	106
2024 Q1	$96.7M	Sell	2,257,206 -10,000	-0.4%	-$422K	0.22%	120
2023 Q4	$92.4M	Buy	2,267,206 +1,157,006	+104%	+$66.3M	0.23%	106
2023 Q3	$56M	Buy	1,110,200 +95,500	+9%	+$3.08M	0.15%	176
2023 Q2	$42.2M	Sell	1,014,700 -38,102	-4%	-$1.07M	0.1%	238
2023 Q1	$25M	Buy	+1,052,802	New	+$24.7M	0.06%	330

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes's GPCR Position: Q4 2025 in Review

Federated Hermes sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 4,500 shares — an estimated $126K sold.

Federated Hermes first reported a position in GPCR in Q1 2023 and held it in 11 quarters. The position peaked at $106M in Q3 2024. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

Federated Hermes reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
Federated Hermes sold 4,500 Structure Therapeutics shares in Q4 2025, an estimated $126K.
Federated Hermes first reported a position in Structure Therapeutics in Q1 2023 and held it in 11 quarters.
Federated Hermes's Structure Therapeutics position peaked at $106M in Q3 2024.
197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on Federated Hermes's 13F filing for Q4 2025, filed 12 Feb 2026.